← Home / BECTON DICKINSON & CO (BDX)
Stock Analysis
BECTON DICKINSON & CO (BDX)
BDX
BDX · Healthcare • Medical Devices
165.45 -1.75%
Track BDX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BDX price is:
52W Range Position
60%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 13:45 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 185.39. Holding above 154.96 keeps the current thesis intact.
⚖️
Fundamentals
Weak / Negative
Price Structure
Constructive
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
154.96
Break Above
Confirmation improves above resistance.
185.39
🎯
Next Objective
Pattern-derived target if setup continues.
194.64
×
Thesis Break
Scenario weakens below invalidation.
Below 154.96
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
20
$
Debt Financing
HIGH
BDX debt financing update
Subsidiary Notes Offering On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”) and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company (“BD”), i...
8-K Filing SEC EDGAR
MAY
12
$
Debt Financing
HIGH
BDX debt financing update
On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”), entered into an u...
8-K Filing SEC EDGAR
MAY
7
Financial Results
HIGH
BD Reports Second Quarter Fiscal 2026 Financial Results
• Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN • GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively • Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter • Company reaffirms revenue growth guidance...
8-K Filing SEC EDGAR
What's Driving BDX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 185.39 for confirmation and 154.96 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 154.58 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Triangle Compression / SYM / UP
State
Back Inside
Trigger
166.79
Target
194.64
Risk / Invalid
157.70
Downtrend Structure
Downtrend breakout active · 2 bars old · score 95
Trigger
160.94
First Resistance
164.52
Target
188.93
Invalidation
160.94
Compression
40%
How to read this setup
Active technical structure detected. Use the chart overlays, support, resistance and invalidation levels to manage confirmation and risk.
Price Chart
BDX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Value
Value-oriented setup
Sales and book multiples are contained.
Market Cap
$46.4B
Company size
EV
$61.1B
Debt-adjusted value
P/E
40.8
Premium
P/S
2.2
Low sales multiple
P/B
1.9
Low book multiple
EV/Sales
2.9
Low sales multiple
EV/EBIT
27.5
Reasonable
P/FCF
17.4
Low multiple
FCF Yield
5.75%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Long-term structure remains supportive
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
Revenue Growth
Weak
Profitability
Negative
Cash Flow
Healthy
Balance Sheet
Manageable
💵 Revenue
4.71B
↘ Weak
📈 Net Income
-311.00M
↘ Negative
🧮 EPS (Basic)
-1.11
↘ Negative
BECTON DICKINSON & CO
Healthcare • Medical Devices